%0 Journal Article
%T Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC
%A Fuxia Xie
%A Mengdan Li
%A Xingguo Jing
%J Advances in Bioscience and Biotechnology
%P 151-161
%@ 2156-8502
%D 2023
%I Scientific Research Publishing
%R 10.4236/abb.2023.144010
%X Immune checkpoint inhibitors (ICIs), targeting programmed cell death
protein-1 (PD-1) and its ligand (PD-L1), have changed the treatment history of
lung cancer, especially in the field of non-small cell lung cancer (NSCLC). <sup>18</sup>F-FDG
PET/CT, as a noninvasive and effective examination technique, reflects the
location and functional information of tumor lesions through the metabolic
level of glucose. Studies have shown that PD-L1 may affect the sugar metabolism
of tumor cells. Therefore, <sup>18</sup>F-FDG PET/CT can be used to predict the
expression of PD-L1 and evaluate the efficacy of immunotherapy. This article
mainly introduces the relationship between PD-L1 expression and NSCLC, the advantages
of <sup>18</sup>F-FDG PET/CT, the imaging mechanism of <sup>18</sup>F-FDG
PET/CT based on PD-L1 and its research progress in NSCLC, and the role of <sup>18</sup>F-FDG
PET/CT in the response and efficacy evaluation of immunotherapy in NSCLC, aiming
to provide a reference for the clinic.
%K &lt
%K sup&gt
%K 18&lt
%K /sup&gt
%K F-FDG PET/CT
%K PD-L1
%K Immune Checkpoint Inhibitors
%K Non-Small Cell Lung Cancer
%K Immunotherapy
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=124360